5MO Phase II ETOP ADEPPT trial: Adagrasib in patients with KRASG12C-mutant NSCLC who are elderly or have poor performance status - Final results

ESMO Open 2026 Open access

Read full text
Authors: J. Naidoo, C. Lindsay, A. Vervita, B. Massuti Sureda, Karin Ribi, G. Metro, M.T. Moran Bueno, M.A. Sala Gonzalez, T. Berghmans, E. Nadal, M.R. Garcia Campelo, Adolfo Favaretto
+8 more P. Espinosa Olarte, M. Domine Gomez, H. Roschitzki-Voser, Barbara Ruepp, A. Gasca, Urania Dafni, S. Peters, R.A. Stahel
DOI: 10.1016/j.esmoop.2026.106312
Cited by: 2

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Protein Kinase Regulation and GTPase Signaling Melanoma and MAPK Pathways

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106312–106312
Publication date
17 March 2026
Language
EN